anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Rural women living with AIDS (WLA) in India continue to face profound challenges in accessing and following treatment regimens, caring for family members, and maintaining positive mental health. Furthermore, they are generally underweight and malnourished, with adherence to antiretroviral therapy (ART) at levels lower than 50%. While the Indian Government's National Rural Health Mission utilizes a successful model to address the health needs of the rural population by training village women as Ashas (Accredited Social Work Activists) to enhance health of pregnant women and their infants, the focus on rural WLA needs to be significantly strengthened. U.S. and Indian collaborators recently completed an R34 pilot study which has demonstrated successful improvement in ART adherence, CD4 levels, and physical and mental health among rural Indian WLA. In total, 34 rural intervention WLA were supported by grant-trained, HIV-focused Ashas who provided assistance to WLA in decreasing barriers to ART adherence and provided protein supplementation compared to equal numbers of usual care WLA who received minimal protein supplementation. While very successful, our Asha pilot study monitored only WLA, despite the fact that many rural children are also at risk for delayed physical growth and psychomotor development. More importantly, we were not able to separate the nutritional component from the care and support component of the Asha, did not incorporate nutritional biomarkers, and were limited by only a six-month follow-up. In light of the mandate to advance both the science of nutrition and sustainability in real settings, our experienced team proposes to build on and extend our successful pilot work to meet this need, by assessing the incremental advantages of nutritional support to Asha care and support alone, and the impact of these programs on an index child (oldest between 3-8 years). In addition, we will take advantage of rural India's excellent mobile phone coverage and computer technology for both wireless data collection and data transfer. The proposed longitudinal study will use a 2x2 factorial design, specifically, 1) Asha support alone for WLA , vs. 2) Asha support for WLA + nutrition (food-based) training, vs. 3) Asha support for WLA + food supplementation, vs. 4) Asha support for WLA + nutrition training + food supplementation, to test the effects of nutrition training and/or food supplementation on primary outcomes of anthropometric parameters and immune status (CD4 levels) of the WLA at 6-, 12- and 18-month follow-up; and secondarily on ART adherence, psychological health, nutritional adequacy and lipid status of the WLA over time. Based upon reviewers' comments, among index children, we streamlined our assessments to include anthropometric parameters and psychomotor development; and among those HIV positive, immune status.
Compressed tablets of pharmaceutical materials which are low melting or adhesive in nature and are not readily compressed by standard procedures, may be moulded by compression under a low compression force e.g. of 2 to 8 tons per sq. inch, by a punch within a die cavity which is subjected to a cleaning operation by the alternating sequential production therein of a tablet from an abrasive material under a high compression force e.g. 15 to 25 tons per sq. in. Preferably the low compression force is achieved with a punch penetration into the cavity of up to 1/8 in., and the high compression force with a penetration of at least 3/8 in.  Preferably the process is operated on a multiple cavity rotary tablet press provided with a hopper for each of the materials and whereby one tablet of each material is produced from each die for each complete revolution of the head.  The abrasive material is preferably one or more of lactose, wood, cellulose, magnesium hydroxide, tricalcium phosphate, and dicalcium phosphate.  The low melting material may be anhydrose lactose with stated combinations and proportions of wood cellulose, magnesium stearate and magnesium hydroxide or may be tricalcium phosphate with lactose, starch, acacia and magnesium stearate.  A suitable granulation comprises, in weight proportions, at least 50% of low melting material, 10-30% filler, 5 to 20% disintegrating agent, 2-15% binding agent and 1-5% lubricant.  In a preferred tybamate granulation formulation, 67 parts thereof were coated with 3.5 parts gelatin followed by admixture with 13 parts wood cellulose and further coating with 1.5% of starch from a 5% concentration paste; the granules thus obtained were dried and admixed with 3 parts wood cellulose, 10.5 parts starch and 1.5 parts stearic acid.  Suitable suppository granulations may contain a bismuth salt, benzocain and meprobamate with polyethylene glycol and a filler; sodium bicarbonate and sodium biophosphate may be contained in efferescent laxative suppository compositions.
The design, synthesis, and use of cyclic compounds, including cyclic polyamides, is described. Such compounds comprise at least two polymer portions, one of which comprises at least three molecular units, and the oth er comprises at least four molecular units. At least one molecular unit of such  a compound is a hydrogen bond donor or acceptor. The polymer portions are covalently linked to form a cycle. These compounds are capable of targeting specific nucleotide sequences in double-stranded nucleic acids, particularly  double-stranded DNA. Accordingly, such compounds can be used to modulate, e.g., increase or decrease, the expression of one or more genes in vitro or in vivo.
Health Belief Model Based Motivational Interview Group The application will be made by the researcher who has been trained in motivational interviewing techniques. Motivational interviews based on Health Belief Model will be made by telephone to mothers who have daughters studying in high school. There will be 3 interviews with mothers based on the benefits, barriers, sensitivity and severity perception structures of the Health Belief Model regarding HPV infection and vaccination, and each interview will last 15-20 minutes. One week after each interview, the questionnaire/scale forms will be sent via whatsapp and applied.
A process and a signal processing unit determine a pneumatic parameter (P mus ) for the spontaneous breathing of a patient. The patient is ventilated mechanically by a ventilator. A lung-mechanical model ( 20 ) and a gradient model ( 22 ) are preset. The lung-mechanical model ( 20 ) describes a relationship between the pneumatic parameter (P mus ) as well as a volume flow signal (Vol′), a volume signal (Vol) and/or a respiratory signal (Sig), which can be measured. The gradient model ( 22 ) describes a value for the pneumatic parameter (P mus ) as a function of N chronologically earlier values of the pneumatic parameter (P mus ) or of a variable correlating with the pneumatic parameter (P mus ). N values for the correlating variable are determined at first. At least one additional value is subsequently determined for the pneumatic parameter (P mus ). N chronologically earlier values of the correlating variable, current signal values, the lung-mechanical model ( 20 ) and the gradient model ( 22 ) are used for this purpose.
Attention to symptoms of heart failure and weight gain are central tenets in heart failure patient education and self-care. A key self-care skill for heart failure patients is the early detection of subtle changes in symptoms. Daily diary use can be one method for patients to acknowledge and attend to their symptoms. This study is examining if the use of a diary in the form of an app on a mobile phone will improve patient outcomes. Participants will be randomized to one of two groups-- usual care or the Movn mobile application. Participants randomized to the mobile app will be asked to record their weight and any symptoms every day over the course of two months.
Group randomly receiving amino acid moisturizing cream as the treatment cream for 3 weeks. Fifteen (15) gram tubes are dispensed at the beginning of each week and will be applied twice daily, by the subject, during the 3 week treatment phase.
FIELD: medicine.SUBSTANCE: group of inventions refers to medicine, namely to immunology and veterinary medicine, and can be used to produce a polyvalent vaccine against anaerobic enterotoxemia of young cattle. For this purpose, the vaccine is made of Cl. perfringens cultures of types A – N28, C – N3 and D – N91, which were grown on meat-casein medium in a reactor at +37 °C for 4-16 hours depending on the time of toxicity formation of a specific strain. Obtained cultures containing highly active toxins with accumulation are used: Cl. perfringens type D not less than 2,000 DLM/cm, type A of not less than 100 DLM/cmand type C of not less than 6,000 DLM/cmfor white mice into which formalin with 37 % of formaldehyde content of culture liquid is added to culture reactor after culturing, preset pH 7.2. Inactivation was carried out at +37 °C for 7 days, obtained cultures are centrifuged, supernatant is used to produce antigen. To deposit the antigens in the culture liquid, 18 % of a three-percent sterile solution of aluminum hydroxide is added, thoroughly stirred and left at temperature of +20 °C for 2–5 days until complete clarification of the supernatant, and then decanted about 70 % of the supernatant fluid to obtain an inactivated vaccine. Group of inventions also relates to use of the obtained polyvalent vaccine against young cattle anaerobic enterotoxemia.EFFECT: use of this group of inventions makes it possible to increase safety of young cattle, protecting against infectious anaerobic enterotoxemia of cattle.3 cl, 2 tbl
The control group is made up of patients, without age limit, who underwent an outpatient surgery from 01/09/19 to 28/02/20 inclusive and accepted post-operative monitoring by SMS. These patients leaves the hospital with instructions and prescriptions.
The patient will receive the gammaCore (nVNS) device and a video instruction will be use to explain how to properly handle the device. Treatment can only start after eligibility has been fully checked and all data collected at screening have been keyed into the trial database.

The patient will be instructed to use the nVNS in place of the rescue medications. When the nauseas gets bad enough that they feel to use a rescue medication they will first use the device on one side of the neck for two 2-minute stimulations and wait fifteen minutes to check if the stimulation works. If this does not help either, they will stimulate with an additional 2 stimulations and wait for another fifteen minutes. If there is no improvement rescue medication will be used. nVNS can be used up to, but no more than, 8 times a day.
Intrahepatic cholangiocarcinoma (ICC) is a highly malignant neoplasm prone to metastasis. Whether cancer-associated fibroblasts (CAFs) affect the metastasis of ICC is unclear. Herein, ICC patient-derived CAF lines and related cancerous cell lines were established and the effects of CAFs on the tumor progressive properties of the ICC cancerous cells were analyzed. CAFs could be classified into cancer-restraining or cancer-promoting categories based on distinct tumorigenic effects. The RNA-sequencing analyses of ICC cancerous cell lines identified polycomb group ring finger 4 (PCGF4; alias BMI1) as a potential metastasis regulator. The changes of PCGF4 levels in ICC cells mirrored the restraining or promoting effects of CAFs on ICC migration. Immunohistochemical analyses on the ICC tissue microarrays indicated that PCGF4 was negatively correlated with overall survival of ICC. The promoting effects of PCGF4 on cell migration, drug resistance activity, and stemness properties were confirmed. Mechanistically, cancer-restraining CAFs triggered the proteasome-dependent degradation of PCGF4, whereas cancer-promoting CAFs enhanced the stability of PCGF4 via activating the IL-6/phosphorylated STAT3 pathway. In summary, the current data identified the role of CAFs in ICC metastasis and revealed a new mechanism of the CAFs on ICC progression in which PCGF4 acted as the key effector by both categories of CAFs. These findings shed light on developing comprehensive therapeutic strategies for ICC.
Patients in the study were divided into two main groups according to the standard fresh gas flow administered (3-6 L/min). Each main group was then divided into subgroups as follows: sevoflurane + remifentanil, desflurane + remifentanil, or propofol + remifentanil (TIVA). These six groups were further divided into two groups according to use or non-use of a heat and moisture exchanger (HME) filter.
AIM: We used a wearable carotid Doppler patch to study carotid blood flow patterns in a porcine model of cardiac arrest to identify return of spontaneous circulation (ROSC) and hemodynamics associated with different arrhythmias and the quality of compressions.
METHODS: Twenty Landrace pigs were used as models of cardiac arrest following a standard protocol. Carotid blood flow was monitored continuously using noninvasive ultrasound. Carotid spectral waveforms were captured during various arrhythmias and CPR. Typical carotid blood flow waveforms were recorded at the time of ROSC, and hemodynamic changes were compared with carotid blood flow parameters.
RESULTS: The results showed that the carotid blood flow waveforms varied with ventricular arrhythmia type. During CPR, compression depth correlated significantly with carotid maximal velocity (Vmax) (Spearman correlation coefficient (r) = 0.682, P < 0.001) and velocity-time integral (VTI) (r = 0.794, P < 0.001). Vmax and VTI demonstrated moderate predictive value for survival. The regular carotid blood flow pattern towards the brain was observed during ROSC, concurrent with compression waveforms. After ROSC, VTI and carotid pulse volume (cPV) showed similar trends as stroke volume (SV). The carotid minute volume (cMV) exhibited a similar trend as cardiac output (CO).
CONCLUSIONS: Carotid blood flow monitoring could provide valuable information about different arrhythmias as well as the quality of CPR. Carotid flow monitoring allows for timely and effective identification of ROSC. In addition, it may provide valuable hemodynamic information after ROSC.
MBCT+w uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The MBCT+w sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with 90-minute weekly meetings that will focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. MBCT+w uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
During a properly coordinated swallow, the oropharynx, larynx, and hypopharynx undergo a series of movements that serve to prepare and expand the pharyngoesophageal segment (PES), which is the inlet into the esophagus. Under normal circumstances, a food bolus is safely propelled from the oropharynx, through the PES, and into the esophagus. Surgical and radiation therapy in the head and neck, as well as deficiencies such as poor coordination, mistiming, or obstructing lesions may prevent the food bolus from safely entering the esophagus and instead diverting toward the trachea.

A number of patients with severe oropharyngeal dysphagia are not able to tolerate any diet without risking aspiration and subsequent pneumonia, often to a degree severe enough that they cannot manage to safely swallow their secreted saliva. These patients depend on a gastrostomy feeding tube in order to obtain adequate daily nutritional requirements and must suction or spit out their saliva to prevent aspiration and a sensation of asphyxiation. Despite these precautions, many of these patients ultimately suffer life-threatening pneumonia. Investigators will be testing if the use of use of a negative pressure suction in the hypopharynx will reduce the amount of aspiration during Video Fluoroscopic Swallowing Exam (VFSE) among patients with severe oropharyngeal dysphagia
While the search for disease modifying treatment of frontotemporal dementia (FTD) remains elusive, on a day-to-day basis, clinicians struggle to help manage the severe neuropsychiatric symptoms of FTD. Agitation, irritability and aggression are common features of the behavioral variant of FTD and to a lesser extent in primary progressive aphasia, and these symptoms are strongly linked to care partner burden. Unfortunately, current pharmacological options for neuropsychiatric symptoms have limited efficacy. Agitation, aggressive behaviors and irritability in FTD are usually pharmacologically managed with a trial-and-error approach using a combination of trazodone, selective serotonin reuptake inhibitors, antiepileptic drugs, memantine and frequently, antipsychotics. Unfortunately, current pharmacological treatment options for neuropsychiatric symptoms of FTD have limited efficacy and are often based on small case studies or anecdotal evidence. Trazodone has the most support from randomized control trials, but shows limited effectiveness. Therefore, in clinical practice second-generation ('atypical') antipsychotics are commonly used despite a paucity of scientific evidence in FTD. This practice is problematic as antipsychotic use in dementia bears a significant burden of side-effects, including falls, and increased cerebrovascular accidents and mortality. There is a clear need for new treatments using novel mechanisms for neuropsychiatric symptoms in FTD.

One promising candidate is nabilone, a synthetic cannabinoid that has shown benefit for agitation in Alzheimer's disease. Nabilone further has potentially beneficial properties on oxidative stress and inflammation in neurodegenerative diseases, mechanisms that have been linked to the pathophysiology of FTD. We propose to conduct the first randomized clinical trial of nabilone for agitation, irritability, and aggression in FTD to obtain data on real-life effectiveness and tolerability. There is a need to obtain data on the efficacy of nabilone on a wide variety of neuropsychiatric symptoms beyond agitation in FTD, while also ensuring the safety of the medication (e.g., is there a detrimental effect on apathy and hyperorality, which are common in FTD). We require data on dosing and tolerability in this population, which is younger on average than Alzheimer's disease subjects from previous studies and therefore may tolerate higher doses of nabilone. The objective of this trial is to obtain robust evidence for the effectiveness and tolerability of nabilone in FTD.
<P>PROBLEM TO BE SOLVED: To obtain a fluorescent contrast agent exhibiting excellent contrasting power and comprising a fluorochrome hardly accumulating in a living organism.  <P>SOLUTION: This fluorescent contrast agent preferably comprises a targeting microcarrier including a fluorochrome, particularly a cyanine-based near-infrared fluorochrome as a near-infrared fluorochrome. A liposome, particularly a liposome enhanced in targeting functions is exemplified as the suitable targeting microcarrier. Desirably, the liposome is prepared by a supercritical carbon dioxide method. Further preferably, the liposome has a polyalkylene oxide chain or a polyethylene glycol chain introduce into the surface of the lipid membrane thereof and has a median particle size of 50-200 nm.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
BACKGROUND AND AIMS: biliary diseases are a major cause of morbidity and mortality for patients and a burden for the healthcare system. The genetic syndrome of low phospholipid-associated cholelithiasis (LPAC) is a little known and rare entity whose treatment with bile salts avoids symptoms, admissions and the need for surgery. The aim of this study was to determine its incidence and characteristics in our center.
METHODS: prospective study performed between February 2021 and September 2022. LPAC was diagnosed if at least two of the following were present: onset of biliary problems < 40 years of age, recurrence of symptoms after cholecystectomy, ultrasound image of hepatolithiasis (multiple echoic foci, comet-tail images, hepatolithiasis with acoustic shadow). Demographic, clinical, genetic (analysis of MDR3 gene mutations) and ultrasound characteristics and their incidence were analyzed in hospital admissions for biliary causes.
RESULTS: thirty-six patients with LPAC were identified. Of these, six were among 237 admissions due to biliary causes in the previous nine months, with an incidence of 2.5 % (95 % CI: 1.17-5.41). By age subgroup, the incidence was 16.7 % in those admitted < 40 years of age and 9.1 % in those < 50. Considering females only, the incidence was 21 % in those admitted < 40 years and 15.8 % in those < 50 years. All patients remained asymptomatic after treatment with ursodeoxycholic acid and there were no new admissions.
CONCLUSIONS: LPAC syndrome is not as uncommon as it may appear, especially in women < 50 years of age admitted with biliary problems. Its correct diagnosis based on simple criteria could avoid a significant number of hospital admissions and unnecessary cholecystectomies.
955,538. Capsules. NATIONAL CASH REGISTER CO. Nov. 15, 1962 [Dec. 22, 1961], No. 43255/62. Heading B8C. A process for producing minute capsules and aggregates thereof, includes the steps of forming an aqueous solution of an encapsulating wall material consisting at least partially of zein at a pH value of 9 to 11, dispersing the intended core material as particulate entities therein by agitation of the system, lowering the pH to below 5.5 to cause phase separation of the wall material which deposits as a solvated solid around each core entity, and cross-linking the deposited wall material to form a rigid waterinsoluble wall, by treating the capsules with a cross-linking agent. Deanimated zein may be used with sodium carboxymethyl cellulose or polyvinylmethylethermaleic anhydride or polyvinylpyrrolidone or gum arabic or polyethylenemaleic anhydride to form the wall material; the pH value is lowered by adding aqueous acetic acid solution to the system. The crosslinking material is glutaraldehyde sol, alphahydroxyadip-aldehyde. In all examples the phase separation is caused by lowering the pH value. All examples are produced at room temperature. The core material may be liquid (oil), crystalline or amorphous and of any shape. The capsules are recovered by filtering, decantation, or centrifuging and then dried.
The Usual Care group will continue to receive insulin as they did before the study. This could be by multiple daily injections (MDI) or by using an insulin pump with or without automation for the 17 weeks of the randomized controlled trial (RCT) Phase. Participants will continue to use their personal continuous glucose monitor (CGM) as they did before the study. The Usual Care group will then use Afrezza and insulin degludec for 13 weeks in the Extension Phase. Dexcom CGM will be provided during the Extension Phase.